Delivery Order SPE2DB24D1201-SPE2DB25FJEEE
- Not listed
- The Defense Logistics Agency awarded a $1,131.87 delivery order to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 237 mg, a testosterone replacement therapy medication. This competitively awarded, firm fixed-price contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,131.88 to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 158 mg, a pharmaceutical product. This non-set-aside, firm fixed-price delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $4,620.72 delivery order to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 237 mg on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award represents a small-value transaction within AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,336.63 to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 237 mg, a testosterone replacement therapy medication. The award, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, was made without set-aside designation through open competition using firm fixed price contracting. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,253.16 to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 198 mg, a testosterone replacement therapy medication. The contract was competitively awarded without set-aside designation on July 21, 2025, with an ultimate completion date of July 22, 2025. Performance will occur at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under firm fixed-price terms and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jatenzo 198 mg capsules (120-count units) valued at $1,131.88 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,131.88 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jatenzo 158 mg capsules (120-count unit). This firm fixed-price delivery order, which is a child contract under a larger vehicle, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. The award utilized no set-aside designation and was competitively awarded through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a firm fixed price ceiling value of $1,483.15. This competitively awarded, non-set-aside delivery order is set for completion by September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,226.39. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside designation was used in this competitive award. The product...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJEEEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,131.87 to AmerisourceBergen Drug Corp for 120 capsules of Jantenzo 237 mg on September 12, 2025, with completion scheduled for September 15, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing pharmaceutical supply agreement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is a child contract stemming from AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide. Jantenzo, a testosterone replacement therapy medication, supports the company's extensive portfolio of specialty medications, brand-name and generic drugs, and specialized medical supplies delivered to defense and healthcare system customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/12/25 |